Related Experiment Video
Updated: Aug 16, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Potential for enhanced oncolytic HSV-1 therapy via SHED as a vehicle against malignant gliomas
Satoru Kida1, Tomoya Oishi1, Tomohiro Yamasaki1
1Department of Neurosurgery, Hamamatsu University School of Medicine, Shizuoka, Japan.
Abstract:
Malignant gliomas are common primary brain tumors. Glioblastoma carries a poor prognosis, with median survival of less than 2 years. Given the urgent need for novel therapies, oncolytic virus (OV) therapy has developed rapidly. However, challenges remain with effective OV delivery to tumor sites and efficient infection of tumor cells. This study investigated the use of stem cells from human exfoliated deciduous teeth (SHED) as a potential vehicle for oncolytic herpes simplex virus-1 therapy (SHED-OV) to enhance treatment efficacy. SHED-OV showed a greater reduction in tumor cell viability in vitro than direct OV infection. Migration assays revealed that SHED-OV actively migrated toward glioma cell-conditioned medium, demonstrating their tumor-homing ability. In vivo experiments demonstrated significantly prolonged survival in both the glioma cell/SHED-OV co-implantation group and the OV-infected glioma cell group compared with controls. In a glioma stem cell model, both SHED-OV and OV alone significantly improved survival compared with controls, with SHED-OV achieving anti-tumor effects comparable to those of direct OV administration and complete tumor regression in a subset of mice. SHED-OV also exhibited tumor-homing ability. These results suggest that SHED could serve as an effective vehicle for OV delivery, potentially improving tumor infection and therapeutic efficacy.
Insights
Stem cells from human exfoliated deciduous teeth (SHED) loaded with oncolytic herpes simplex virus-1 (SHED-OV) show promise for treating malignant gliomas. SHED-OV effectively targets tumors and enhances survival in preclinical models.
Area of Science:
- Neuro-oncology
- Stem Cell Therapy
- Virology
Background:
- Malignant gliomas, particularly glioblastoma, have a poor prognosis, necessitating novel therapeutic strategies.
- Oncolytic virus (OV) therapy offers a promising avenue, but challenges in tumor delivery and infection efficiency persist.
Purpose of the Study:
- To investigate the potential of stem cells from human exfoliated deciduous teeth (SHED) as a delivery vehicle for oncolytic herpes simplex virus-1 (OV) therapy (SHED-OV).
- To evaluate the efficacy of SHED-OV in enhancing anti-tumor effects against malignant gliomas in vitro and in vivo.
Main Methods:
- In vitro assessment of SHED-OV's effect on glioma cell viability compared to direct OV infection.
- Migration assays to evaluate the tumor-homing ability of SHED-OV.
- In vivo studies in glioma models to assess survival rates and anti-tumor effects of SHED-OV.
Main Results:
- SHED-OV demonstrated superior reduction in tumor cell viability in vitro compared to direct OV administration.
- SHED-OV exhibited significant tumor-homing capabilities, migrating towards glioma cell-conditioned medium.
- In vivo studies showed significantly prolonged survival in both SHED-OV and OV-treated groups, with SHED-OV achieving comparable anti-tumor effects and complete tumor regression in some mice.
Conclusions:
- SHED serves as an effective vehicle for OV delivery, enhancing tumor infection and therapeutic efficacy.
- SHED-OV holds potential for improving treatment outcomes in malignant glioma patients.
- Further research into SHED-mediated OV delivery is warranted for clinical translation.
